Indication
Malignant Melanoma Stage III
3 clinical trials
5 products
Clinical trial
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)Status: Active (not recruiting), Estimated PCD: 2020-01-03
Product
IpilimumabProduct
NivolumabClinical trial
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-11
Product
DomatinostatClinical trial
Multicenter Phase 3 Trial Comparing Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma - NADINAStatus: Active (not recruiting), Estimated PCD: 2024-01-12
Product
Adjuvant nivolumab